US 9,809,637 B2
Transforming growth factor beta receptor II fusion polypeptides
Ravindra Kumar, Acton, MA (US); Asya Grinberg, Lexington, MA (US); Dianne S. Sako, Medford, MA (US); Roselyne Castonguay, Malden, MA (US); and Rita Steeves, Stoneham, MA (US)
Assigned to ACCLERON PHARMA INC., Cambridge, MA (US)
Filed by Acceleron Pharma Inc., Cambridge, MA (US)
Filed on Feb. 16, 2016, as Appl. No. 15/44,883.
Application 15/044,883 is a continuation of application No. 14/465,182, filed on Aug. 21, 2014, abandoned.
Claims priority of provisional application 61/906,849, filed on Nov. 20, 2013.
Claims priority of provisional application 61/906,270, filed on Nov. 19, 2013.
Claims priority of provisional application 61/868,713, filed on Aug. 22, 2013.
Prior Publication US 2016/0376341 A1, Dec. 29, 2016
Int. Cl. C07K 14/71 (2006.01); C07K 14/495 (2006.01); C07K 16/22 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/71 (2013.01) [C07K 14/495 (2013.01); C07K 16/22 (2013.01); A61K 38/00 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)] 9 Claims
1. A Transforming Growth Factor β Receptor II (TβRII) fusion polypeptide comprising a first amino acid sequence from the extracellular domain of TβRII and a heterologous amino acid sequence, wherein the first amino acid sequence consists of an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 13,
wherein the fusion polypeptide does not include the amino acids corresponding to amino acids 1-22 and 185-592 of SEQ ID NO: 6;
and wherein the fusion polypeptide binds Transforming Growth Factor β1 or Transforming Growth Factor β3.